Eterna Therapeutics
ERNA
7 hedge funds and large institutions have $555K invested in Eterna Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more capital invested
Capital invested by funds: $332K → $555K (+$223K)
40% more funds holding
Funds holding: 5 → 7 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$162K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$108K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$108K |
| 4 |
VF
Virtu Financial
New York
|
+$108K |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$54.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Eagle Asset Management
St Petersburg,
Florida
| $175K | +$54.2K | +1 | +20% |
|
|
2
Citadel Advisors
Miami,
Florida
| $85K | +$108K | +2 | +200% |
|
|
3
Renaissance Technologies
New York
| $74K | +$162K | +3 | New |
|
|
VF
4
Virtu Financial
New York
| $68K | +$108K | +2 | New |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $65K | +$108K | +2 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $39K | – | – | – |
|
|
NSIM
7
North Star Investment Management
Chicago,
Illinois
| $35K | – | – | – |
|
8
BlackRock
New York
| $6K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $6K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
11
Vanguard Group
Malvern,
Pennsylvania
| – | -$36K | -1 | Closed |
|
ERNA Hedge Fund Activity: Q1 2021 in Review
7 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2021, worth a combined $555K — up 67% from $332K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ERNA positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $162K. The largest seller was Vanguard Group, exiting entirely with an estimated $36K sold.
- 7 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2021, up from 5 in Q4 2020.
- Funds reported $555K of Eterna Therapeutics stock for Q1 2021, up 67% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q1 2021 and 1 closed out, a net change of +2 holders.
- The largest Eterna Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $162K added.
- The largest Eterna Therapeutics seller in Q1 2021 was Vanguard Group, an estimated $36K sold.
Based on aggregated 13F filings for Q1 2021.